Agenus and Zydus Finalize $141m Immunotherapy Collaboration Deal
ByAinvest
Saturday, Jan 17, 2026 6:36 am ET1min read
AGEN--
Agenus and Zydus Lifesciences have completed a $141m strategic collaboration to accelerate the global development and potential commercialization of their botensilimab and balstilimab (BOT/BAL) immunotherapy combination program. The deal secures funding and sustained biologics manufacturing capacity in the US for Agenus and provides Zydus with exclusive rights to develop and commercialize BOT/BAL in Sri Lanka and India. Agenus is eligible for a 5% royalty on net sales from these markets and has initiated the global BATTMAN Phase III trial.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet